Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medivation and Astellas Pharma have reported preliminary results from an ongoing study that provides additional evidence of the clinical effects and tolerability of MDV3100 in patients with advanced prostate cancer.
Subscribe to our email newsletter
MDV3100 is a triple-acting, pure androgen receptor antagonist in clinical development to treat advanced prostate cancer.
Bone marrow biopsies are carried out in the study to evaluate the impact of MDV3100 on tumors that had metastasized to the bone marrow.
Medivation CMO Lynn Seely said the preliminary results from this study confirm MDV3100’s anti-tumor effects and tolerability profile seen in their previously reported Phase 1-2 trial and provides further support for the selection of 160mg per day as the optimal Phase 3 dose.
"The bone marrow biopsy data also confirm that MDV3100 inhibits nuclear translocation of the androgen receptor," Seely said.